Management
President & Chief Executive OfficerMahesh V. Patel, Ph.D.
Mahesh V. Patel, Ph.D. has served as our President and Chief Executive Officer and as a member of our Board of Directors since 1997. Dr. Patel has more than 30 years of experience in strategic planning, technology assessment/development, technical management and product research and development in the area of drug discovery support, drug delivery and product line extensions. Prior to co-founding Lipocine in 1997, he led drug delivery research and development at Pharmacia and Upjohn. Dr. Patel received a B.Pharm from Karnataka University in India, a M.S. in Physical Pharmacy at the University of Cincinnati and a Ph.D. in Pharmaceutics from the University of Utah. We believe Dr. Patel’s dual role as an executive officer and director gives him unique insights into the day-to-day operations of our company and our strategic planning and clinical development.
Principal Accounting Officer & Corporate ControllerKrista Fogarty
Krista Fogarty, MAcc, has served as our Principal Accounting Officer since January 2022 and our Corporate Controller since October 2018. Ms. Fogarty previously served as Chief Financial Officer at Alternative Behavior Strategies, a provider of ABA therapy services from 2017 to 2018, and as Controller and Associate VP Business Operations at Navigen, a pharmaceutical discovery and drug development company, from 2016 to 2017. Prior to that she served as VP Finance at Lineagen, a personal genomics and biotechnology company from 2013 to 2016. Ms. Fogarty also previously served as Corporate Controller at NPS Pharmaceuticals, a biotechnology company. Ms. Fogarty received a B.S. in Accounting from Utah State University and also received a MAcc from Utah State University
Chief Medical DirectorAnthony DelConte, M.D.
Dr. Anthony DelConte brings more than three decades of experience spanning private practice, academia, and pharmaceutical medicine. He currently serves as Chief Medical Director at Lipocine and holds a Senior Adjunct Professorship in Food, Pharma, and Healthcare at Saint Joseph’s University.
Dr. DelConte earned his BS from Saint Joseph’s University and his medical degree from the University of Pittsburgh. He remained in Pittsburgh for his training in obstetrics and gynecology at Magee-Women’s Hospital. He is also the founder of DC Medical Consulting LLC, a firm dedicated to guiding biotechnology companies in clinical development, medical affairs, and drug safety strategy.
Earlier in his career, Dr. DelConte served as Chief Medical Officer at Auxilium (now part of Endo Pharmaceuticals), where he provided strategic medical leadership across the company’s development pipeline and marketed portfolio. He also held a series of increasingly senior roles at Wyeth (now Pfizer) and Novartis Pharmaceuticals, contributing to the clinical development, regulatory strategy, and medical affairs support of several key assets and flagship brands. His work spanned early-stage development through commercialization, helping ensure scientific rigor, patient safety, and strong medical guidance across global programs.
VP Product DevelopmentNachiappan (Chidu) Chidambaram, Ph.D.
Nachiappan (Chidu) Chidambaram, Ph.D. has served as our Senior Vice President, Research and Development since December 2022 and has over 20 years of product development experience in pharma and biotech. Prior to his promotion, Dr. Chidambaram served as our Vice President, Product Development, since July 2014. Prior to being promoted to Vice President, Product Development, Dr. Chidambaram served in various product development leadership roles with the Company including Associate Director, Product Development, from 2007 to 2014. Prior to joining Lipocine in 2007, Dr. Chidambaram served as the Group Leader at Banner Pharmacaps from 2000 to 2007. He received his Ph.D. in Pharmaceutics from the University of Connecticut in 2000.
VP of Clinical DevelopmentBenjamin Bruno, PharmD, Ph.D
Dr. Benjamin Bruno has been a clinical trialist for the past 8 years, 6 of which have been with Lipocine focused on drug development. He received his BS in biology from the University of Michigan, and Doctor of Pharmacy (PharmD) and PhD in Pharmaceutics from the University of Utah. His areas of expertise include pharmaceutical clinical development including clinical program and trial design, execution, and analysis, as well as regulatory communication and dissemination of study results.
